HEA 3050 Module 3 Menopause Paper: Hormone Therapy Decisions After the Women's Health Initiative Example

Hot Flashes and Headlines: What the Women's Health Initiative Means for a Woman of Fifty-One

Student Name

B.S. in Health Studies, Thomas Edison State University

HEA-3050: Women's Health

Mentor Name

Month Day, Year

Hot Flashes and Headlines: What the Women's Health Initiative Means for a Woman of Fifty-One

Introduction

In July 2002, newspapers across the country reported that hormone therapy for menopause raised the risk of breast cancer, heart attack and stroke. Within a year, prescriptions fell sharply. Two decades later, many women in their early fifties remain afraid of hormone therapy, while others have been told it is safe again. This paper explains what the Women's Health Initiative found, how its findings were reinterpreted by age and time since menopause and how an individual woman might use that evidence.

The Woman

Dana is invented for this paper. She is 51, a middle school assistant principal in Princeton, and her last period came fourteen months ago. Hot flashes hit her eight to ten times daily, and night sweats wake her three or four times before morning. She is tired at work and short with her teenage son. She has never smoked, her blood pressure readings are normal and she has never had breast cancer, a blood clot, a stroke or heart disease. Her mother broke a hip at 74. Her friend told her that hormones cause cancer.

The 2002 Trial

The estrogen plus progestin arm of the trial (Writing Group for the Women's Health Initiative Investigators, 2002) randomized 16,608 women past menopause, aged 50 to 79 and with a uterus, to conjugated equine estrogens with medroxyprogesterone acetate or to placebo. Investigators halted the trial early, a little over five years in on average, once invasive breast cancer had crossed its safety boundary and the overall balance of harms exceeded benefits. Women taking hormones had more coronary heart disease events, strokes, blood clots in the lungs and invasive breast cancers, and fewer hip fractures and colorectal cancers. In absolute terms, for 10,000 women taking the drugs for a year, there were about seven more heart events, eight more strokes, eight more pulmonary emboli and eight more breast cancers, and six fewer colorectal cancers and five fewer hip fractures.

The Women Who Were Studied

The average participant was 63 years old, more than a decade past menopause, and the trial was designed to test whether hormones prevent chronic disease, not whether they relieve symptoms. Women with severe hot flashes were less likely to enroll. These facts mattered when researchers later asked what the results meant for younger women seeking relief.

Extended Follow-Up

Manson et al. (2013) reported results from both hormone trials, estrogen plus progestin and estrogen alone for women without a uterus, through 13 years of follow-up. Risks did not persist for most outcomes after hormones were stopped, although an elevated breast cancer risk remained with estrogen plus progestin. Women in their fifties faced smaller absolute risks of harm than women in their sixties and seventies. The authors concluded that hormone therapy should not be used to prevent chronic disease but could reasonably be used to relieve symptoms in some women in the early years after menopause.

The Current Position Statement

In its position statement (North American Menopause Society, 2022), the society judged the balance of benefit and risk favorable for women without contraindications who are younger than 60 or whose menopause began less than a decade earlier, both for treating bothersome hot flashes and for preventing bone loss in those at elevated risk. For women who begin hormones past age 60, or a decade or more beyond their final period, the balance is less favorable because the absolute chances of heart disease, stroke, clots and dementia are higher at that point. The statement recommends individualizing the type, dose, route and duration of therapy and reassessing regularly.

Weighing the Decision

For Dana, the evidence suggests that hormone therapy is a reasonable option to discuss with her clinician. Her symptoms are frequent and are disrupting sleep, work and family life. She is within two years of menopause, under 60 and without contraindications. Her mother's hip fracture adds a possible bone benefit. Against this, she would take on a small increase in the risk of breast cancer with combined therapy over several years and a small risk of blood clots, which may be lower with estrogen through the skin than by mouth.

Alternatives exist. Some antidepressants and other nonhormonal medicines reduce hot flashes, though less effectively, and cognitive behavioral therapy can reduce how much hot flashes disturb daily life. Lifestyle changes such as layering clothes, keeping the bedroom cool and limiting alcohol help some women.

Personal and Cultural Influences

Dana's fear came from a friend's warning and from headlines she half remembers. Many women her age heard the 2002 news at a time when their mothers stopped hormones abruptly. Clear explanation of absolute rather than relative risk can help. A 26 percent increase in breast cancer risk sounds frightening; eight more cases a year among 10,000 women is easier to weigh against symptoms that affect every day.

Limits

The trials tested one estrogen and one progestin, both by mouth, so their results may not apply to other types, doses or routes, such as estradiol through the skin. Participants were mostly white, and evidence for Black, Hispanic and Asian women is thinner. This paper describes evidence; Dana's decision belongs to her and her clinician.

Conclusion

The Women's Health Initiative answered an important question: hormone therapy should not be used to prevent heart disease in older women. Its headlines, however, were heard as a verdict on all hormone therapy for all women. Later analyses by age and the current position statement suggest that for a healthy woman like Dana, early in menopause and troubled by symptoms, the decision deserves a fresh conversation with her clinician, based on her own history and her own priorities.

References

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., . . . Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. https://doi.org/10.1001/jama.2013.278040

North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028

Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321